While in solid tumor-derived cell lines, NR4A1 and NR4A2 expression are high, and both receptors exhibit pro-oncogenic activities, in blood-derived tumors (leukemias and lymphomas), NR4A expression, particularly of NR4A1 and NR4A3, is low [26,35]. This evidence concerns the gene NR4A3 and leukemia.